Will you now recommend enfortumab and pembrolizumab for most patients with metastatic urothelial carcinoma, regardless of platinum eligibility, based on the EV 302 presentation at ESMO 2023?
1
1 Answers
Mednet Member
Medical Oncology · University of Virginia
The data presented at ESMO were paradigm-shifting. Within the constraints of insurance coverage, I will offer EVP to all patients with untreated metastatic urothelial cancer who are otherwise candidates for this therapy.